Author:
Greenwell Kathriena,Hussain Lala,Lee David,Bramlage Matthew,Bills Gordon,Mehta Apurva,Jackson Amie,Wexelman Barbara
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Fda.gov (2018) FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer [online]. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590005.htm (Accessed 7 Apr 2018)
2. Romond E, Perez E, Bryant J, Suman V, Geyer C, Davidson N, Tan-Chiu E, Martino S, Paik S, Kaufman P, Swain S, Pisansky T, Fehrenbacher L, Kutteh L, Vogel V, Visscher D, Yothers G, Jenkins R, Brown A, Dakhil S, Mamounas E, Lingle W, Klein P, Ingle J, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
3. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley D, Bines J, Gelber R, Piccart M, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131
4. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307–4315
5. Borley A, Mercer T, Morgan M, Dutton P, Barrett-Lee P, Brunelli M, Jasani B (2014) Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network. Br J Cancer 110(8):2139–2143
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献